CG Oncology (NASDAQ:CGON) Director James Mulay Sells 1,964 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 1,964 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $60.12, for a total value of $118,075.68. Following the sale, the director owned 654 shares of the company’s stock, valued at approximately $39,318.48. The trade was a 75.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Mulay also recently made the following trade(s):

• On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The stock was sold at an average price of $73.01, for a total value of $1,138,956.00.

CG Oncology Price Performance

Shares of CGON stock traded up $0.73 on Tuesday, hitting $60.28. 530,632 shares of the company’s stock were exchanged, compared to its average volume of 1,174,573. CG Oncology, Inc. has a 12 month low of $23.65 and a 12 month high of $75.50. The stock has a market cap of $5.32 billion, a P/E ratio of -25.87 and a beta of 0.31. The company has a 50 day moving average of $64.89 and a 200 day moving average of $56.73.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The company had revenue of $1.08 million during the quarter, compared to analyst estimates of $0.45 million. Sell-side analysts predict that CG Oncology, Inc. will post -2.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CGON has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research report on Monday, April 20th. Wall Street Zen downgraded CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a research report on Monday, May 18th. Finally, Truist Financial reiterated a “buy” rating and issued a $82.00 target price (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, CG Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $81.73.

Hedge Funds Weigh In On CG Oncology

Several large investors have recently bought and sold shares of the company. Bank of America Corp DE raised its position in CG Oncology by 21.8% in the first quarter. Bank of America Corp DE now owns 1,449,364 shares of the company’s stock valued at $98,093,000 after purchasing an additional 259,311 shares during the last quarter. Stempoint Capital LP acquired a new stake in shares of CG Oncology in the first quarter valued at about $13,916,000. California State Teachers Retirement System increased its stake in shares of CG Oncology by 23.6% in the first quarter. California State Teachers Retirement System now owns 51,499 shares of the company’s stock valued at $3,485,000 after buying an additional 9,841 shares during the period. Royal Bank of Canada increased its stake in shares of CG Oncology by 18.6% in the first quarter. Royal Bank of Canada now owns 11,439 shares of the company’s stock valued at $774,000 after buying an additional 1,793 shares during the period. Finally, EcoR1 Capital LLC increased its stake in shares of CG Oncology by 3.5% in the first quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company’s stock valued at $74,583,000 after buying an additional 37,200 shares during the period. 26.56% of the stock is currently owned by institutional investors.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.